News articles about SurModics (NASDAQ:SRDX) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. SurModics earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.028443013156 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Several analysts have recently weighed in on SRDX shares. BidaskClub lowered SurModics from a “sell” rating to a “strong sell” rating in a report on Friday, December 29th. Zacks Investment Research lowered SurModics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $40.00.

Shares of SurModics (NASDAQ:SRDX) opened at $28.10 on Wednesday. SurModics has a fifty-two week low of $21.90 and a fifty-two week high of $34.15. The firm has a market capitalization of $393.24, a P/E ratio of 96.90 and a beta of 0.81.

SurModics (NASDAQ:SRDX) last announced its quarterly earnings data on Wednesday, November 8th. The company reported $0.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.19. SurModics had a return on equity of 6.18% and a net margin of 5.37%. The company had revenue of $20.06 million for the quarter, compared to analyst estimates of $16.98 million. equities research analysts anticipate that SurModics will post -0.44 earnings per share for the current year.

In other news, VP Joseph J. Stich sold 1,000 shares of SurModics stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $30.18, for a total transaction of $30,180.00. Following the sale, the vice president now owns 46,450 shares of the company’s stock, valued at approximately $1,401,861. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.70% of the stock is currently owned by company insiders.

WARNING: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at

About SurModics

Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.

Insider Buying and Selling by Quarter for SurModics (NASDAQ:SRDX)

Receive News & Ratings for SurModics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics and related companies with's FREE daily email newsletter.